Drug Trial Radar · NCT07270848
Dronedarone Rhythm Intervention for Early Atrial Fibrillation
Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,898
Planned (sponsor's estimate)
Start
Jan 1, 2026
Primary completion
Jun 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Inha University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare two commonly used types of medicine for treating atrial fibrillation (also called AF), a condition that causes an irregular heart rhythm. This study is for adults who have been diagnosed with AF within the past year. Researchers want to find out which medicine is more effective, safer, and provides a better quality of life for patients needing to control their heart rhythm. Participants who agree to join the study will be randomly assigned (like flipping a coin) to one of two groups: Group 1: Will receive the medicine Dronedarone. Group 2: Will receive a standard medicine from the 'Class Ic' group (such as flecainide or propafenone). The study will follow participants for at least 12 months. Researchers will compare how well each medicine works to prevent AF from coming back. They will also carefully track any side effects and changes in participants' quality of life during the study.
Conditions
- Atrial Fibrillation (AF)
Interventions
DronedaroneDrug
Dronedarone 400 mg administered orally twice daily.
flecainideDrug
Administered orally according to standard clinical practice.
propafenoneDrug
Administered orally according to standard clinical practice.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy : Recurrence of Atrial FibrillationTime frame: From randomization up to 12 months
- Safety : Rate of Drug Discontinuation Due to Adverse EventsTime frame: Up to 12 months
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Korea University Ansan Hospital
Ansan, South Korea
Soonchunhyang University Bucheon Hospital
Bucheon-si, South Korea
Kosin University Gospel Hospital
Busan, South Korea
Soonchunhyang University Cheonan Hospital
Cheonan, South Korea
Inje University Ilsan Paik Hospital
Goyang, South Korea
NHIS Ilsan Hospital
Goyang-si, South Korea
Myongji Hospital
Goyang-si, South Korea
Hanyang University Guri Hospital
Guri-si, South Korea
Jeju National University Hospital
Jeju City, South Korea
Sejong Chungnam National University Hospital
Sejong, South Korea
Korea University Anam Hospital
Seoul, South Korea
Severance Hospital
Seoul, South Korea
Ewha Womans University Seoul Hospital
Seoul, South Korea
Korea University Guro Hospital
Seoul, South Korea
Wonju Severance Christian Hospital
Wŏnju, South Korea
Inha University Hospital
Incheon, Incheon, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.